Novo Nordisk CEO retains faith in obesity business

CEO Lars Fruergaard Jørgensen is still confident about the future of the pharmaceutical giant’s obesity business, despite investor disappointment over recent developments.

Photo: Stine Bidstrup/ERH

Although investors have punished Novo Nordisk on the stock exchange in an apparent reaction to a couple of obesity-related disappointments, there is still faith in the growth predictions for the obesity market at the firm.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs